Most-Downgraded StocksMost-DowngradedNYSE:NVRO Nevro (NVRO) Stock Forecast, Price & News $19.44 -0.07 (-0.36%) (As of 11:51 AM ET) Add Compare Share Share Today's Range$19.27▼$19.7050-Day Range$18.20▼$24.9652-Week Range$17.88▼$50.54Volume124,136 shsAverage Volume573,821 shsMarket Capitalization$702.17 millionP/E Ratio1,945.95Dividend YieldN/APrice Target$30.62 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Nevro MarketRank™ ForecastAnalyst RatingHold2.14 Rating ScoreUpside/Downside58.1% Upside$30.62 Price TargetShort InterestBearish6.62% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.56Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.96) to ($2.37) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.07 out of 5 starsMedical Sector521st out of 966 stocksSurgical & Medical Instruments Industry61st out of 92 stocks 4.1 Analyst's Opinion Consensus RatingNevro has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 4 buy ratings, 8 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $30.62, Nevro has a forecasted upside of 58.1% from its current price of $19.36.Amount of Analyst CoverageNevro has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.62% of the outstanding shares of Nevro have been sold short.Short Interest Ratio / Days to CoverNevro has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Nevro has recently increased by 27.81%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNevro does not currently pay a dividend.Dividend GrowthNevro does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NVRO. Previous Next 2.5 News and Social Media Coverage News SentimentNevro has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Nevro this week, compared to 3 articles on an average week.MarketBeat Follows3 people have added Nevro to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nevro insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.00% of the stock of Nevro is held by insiders.Percentage Held by Institutions95.52% of the stock of Nevro is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Nevro are expected to grow in the coming year, from ($2.96) to ($2.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nevro is 1,937.94, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 120.50.Price to Earnings Ratio vs. SectorThe P/E ratio of Nevro is 1,937.94, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 107.05.Price to Book Value per Share RatioNevro has a P/B Ratio of 2.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Nevro (NYSE:NVRO) StockNevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation system for the treatment of chronic pain, as well as Senza II and Senza Omnia SCS systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company's Senza HFX iQ IPG system includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system. In addition, it offers surpass surgical and percutaneous leads. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.Read More NVRO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVRO Stock News HeadlinesSeptember 21, 2023 | americanbankingnews.comNevro (NYSE:NVRO) Share Price Passes Below 50-Day Moving Average of $21.12September 18, 2023 | markets.businessinsider.comNew Data Show Health Economic Benefits Of Nevro's High-Frequency Spinal Cord Stimulation TherapySeptember 22, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.September 18, 2023 | prnewswire.comNew Data Demonstrate the Health Economic Benefits of Nevro's High-Frequency Spinal Cord Stimulation TherapySeptember 18, 2023 | insidermonkey.comHere’s Why Nevro Corp. (NVRO) Declined in Q2September 1, 2023 | msn.comNevro: Economic Realities Too Deep To Ignore, Downgrade To HoldAugust 22, 2023 | msn.comCitigroup Maintains Nevro (NVRO) Neutral RecommendationAugust 21, 2023 | markets.businessinsider.comWhat 21 Analyst Ratings Have To Say About NevroSeptember 22, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.August 16, 2023 | finance.yahoo.comNew 24-Month Data Shows Nevro's SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic NeuropathyAugust 10, 2023 | finanznachrichten.deNevro Corp: Nevro announces launch of HFX Connect in Europe and CE marking of expanded labelling for the HFX SCS system.August 10, 2023 | finance.yahoo.comNevro announces launch of HFX Connect™ in Europe and CE marking of expanded labelling for the HFX™ SCS system.August 3, 2023 | markets.businessinsider.comExpert Ratings for NevroAugust 3, 2023 | markets.businessinsider.comPotential Turnaround Ahead for Nevro: Q2 Earnings, Guidance Lag Wall Street EstimatesAugust 3, 2023 | finance.yahoo.comWhy Shares of Nevro Are Down WednesdayAugust 2, 2023 | insidermonkey.comNevro Corp. (NYSE:NVRO) Q2 2023 Earnings Call TranscriptAugust 2, 2023 | msn.comBaird Maintains Nevro (NVRO) Neutral RecommendationAugust 2, 2023 | msn.comJMP Securities Maintains Nevro (NVRO) Outperform RecommendationAugust 2, 2023 | finance.yahoo.comNevro (NVRO) Q2 Earnings Lag Estimates, FY23 View CutAugust 2, 2023 | markets.businessinsider.comJMP Securities Remains a Buy on Nevro Corp (NVRO)July 20, 2023 | msn.comBaird Initiates Coverage of Nevro (NVRO) with Neutral RecommendationJuly 14, 2023 | markets.businessinsider.comRBC Capital Remains a Buy on Nevro Corp (NVRO)July 13, 2023 | finance.yahoo.comNevro Announces Presentations at American Society of Pain & Neuroscience Fifth Annual ConferenceJuly 12, 2023 | finance.yahoo.comNevro to Present at the Canaccord Genuity 43rd Annual Growth ConferenceJuly 6, 2023 | msn.comNevro (NVRO) Price Target Decreased by 7.67% to 38.61June 29, 2023 | msn.comJP Morgan Maintains Nevro (NVRO) Neutral RecommendationJune 28, 2023 | markets.businessinsider.comWhat 17 Analyst Ratings Have To Say About NevroSee More Headlines Receive NVRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nevro and its competitors with MarketBeat's FREE daily newsletter. Email Address NVRO Company Calendar Last Earnings8/01/2023Today9/22/2023Next Earnings (Estimated)11/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNYSE:NVRO CUSIPN/A CIK1444380 Webwww.nevro.com Phone(650) 251-0005FaxN/AEmployees1,087Year FoundedN/APrice Target and Rating Average Stock Price Forecast$30.62 High Stock Price Forecast$57.00 Low Stock Price Forecast$21.00 Forecasted Upside/Downside+56.8%Consensus RatingHold Rating Score (0-4)2.14 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)$0.01 Trailing P/E Ratio1,953.95 Forward P/E RatioN/A P/E GrowthN/ANet Income$3 million Net Margins0.61% Pretax Margin1.00% Return on Equity-32.73% Return on Assets-17.32% Debt Debt-to-Equity Ratio0.64 Current Ratio6.85 Quick Ratio5.30 Sales & Book Value Annual Sales$406.36 million Price / Sales1.74 Cash FlowN/A Price / Cash FlowN/A Book Value$9.14 per share Price / Book2.14Miscellaneous Outstanding Shares36,120,000Free Float35,036,000Market Cap$705.06 million OptionableOptionable Beta0.88 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. D. Keith Grossman (Age 63)Exec. Chairman Comp: $1.75MMr. Roderick H. MacLeod (Age 56)Sr. VP & CFO Comp: $729.61kMr. Kashif Rashid (Age 49)Sr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer Comp: $703.35kMr. Kevin R. Thornal (Age 49)Pres, CEO & Director Mr. Richard B. Carter (Age 52)Chief Accounting Officer Mr. Christofer Christoforou (Age 53)Sr. VP of Technical Operations Mr. Jon R. ShearSr. VP of Corp. Devel.Meredith VornholtVP of Global MarketingDr. David Caraway M.D. (Age 66)Ph.D., Sr. VP & Chief Medical Officer Mr. Donald A. Middlebrook (Age 72)Sr. VP of Clinical & Regulatory Affairs More ExecutivesKey CompetitorsAtrionNASDAQ:ATRIOrthoPediatricsNASDAQ:KIDSBeauty HealthNASDAQ:SKINSilk Road MedicalNASDAQ:SILKArtivionNYSE:AORTView All CompetitorsInsiders & InstitutionsBarclays PLCSold 8,458 shares on 9/21/2023Ownership: 0.037%Virginia Retirement Systems ET ALBought 20,900 shares on 8/22/2023Ownership: 0.058%California State Teachers Retirement SystemBought 670 shares on 8/21/2023Ownership: 0.120%TD Capital Management LLCBought 80,000 shares on 8/16/2023Ownership: 0.234%Quarry LPBought 643 shares on 8/15/2023Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions NVRO Stock - Frequently Asked Questions Should I buy or sell Nevro stock right now? 14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 2 sell ratings, 8 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NVRO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVRO, but not buy additional shares or sell existing shares. View NVRO analyst ratings or view top-rated stocks. What is Nevro's stock price forecast for 2023? 14 brokerages have issued 1 year price objectives for Nevro's stock. Their NVRO share price forecasts range from $21.00 to $57.00. On average, they expect the company's share price to reach $30.62 in the next twelve months. This suggests a possible upside of 56.8% from the stock's current price. View analysts price targets for NVRO or view top-rated stocks among Wall Street analysts. How have NVRO shares performed in 2023? Nevro's stock was trading at $39.60 at the start of the year. Since then, NVRO stock has decreased by 50.7% and is now trading at $19.52. View the best growth stocks for 2023 here. Are investors shorting Nevro? Nevro saw a increase in short interest in August. As of August 31st, there was short interest totaling 2,390,000 shares, an increase of 27.8% from the August 15th total of 1,870,000 shares. Based on an average daily volume of 539,400 shares, the days-to-cover ratio is currently 4.4 days. View Nevro's Short Interest. When is Nevro's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023. View our NVRO earnings forecast. How were Nevro's earnings last quarter? Nevro Corp. (NYSE:NVRO) posted its quarterly earnings data on Tuesday, August, 1st. The medical equipment provider reported ($0.69) EPS for the quarter, missing analysts' consensus estimates of ($0.68) by $0.01. The medical equipment provider earned $108.80 million during the quarter, compared to analysts' expectations of $108.19 million. Nevro had a net margin of 0.61% and a negative trailing twelve-month return on equity of 32.73%. The firm's revenue was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.71) earnings per share. What ETFs hold Nevro's stock? ETFs with the largest weight of Nevro (NYSE:NVRO) stock in their portfolio include Alger Weatherbie Enduring Growth ETF (AWEG), iShares Neuroscience and Healthcare ETF (IBRN) and SPDR S&P Health Care Equipment ETF (XHE).Fidelity Digital Health ETF (FDHT). What guidance has Nevro issued on next quarter's earnings? Nevro issued an update on its third quarter 2023 earnings guidance on Tuesday, August, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $95.00 million-$97.00 million, compared to the consensus revenue estimate of $109.25 million. What is D. Keith Grossman's approval rating as Nevro's CEO? 9 employees have rated Nevro Chief Executive Officer D. Keith Grossman on Glassdoor.com. D. Keith Grossman has an approval rating of 68% among the company's employees. What other stocks do shareholders of Nevro own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), Walt Disney (DIS), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Adobe (ADBE) and Intuitive Surgical (ISRG). What is Nevro's stock symbol? Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO." Who are Nevro's major shareholders? Nevro's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.37%), ArrowMark Colorado Holdings LLC (5.03%), State Street Corp (3.11%), Assenagon Asset Management S.A. (2.76%), Principal Financial Group Inc. (2.00%) and Geode Capital Management LLC (1.94%). Insiders that own company stock include D Keith Grossman, Elizabeth H Weatherman, Kashif Rashid, Kevin C Oboyle, Leslie Stretch, Michael F Demane, Michael F Demane, Niamh Louise Pellegrini and Shawn Mccormick. View institutional ownership trends. How do I buy shares of Nevro? Shares of NVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Nevro's stock price today? One share of NVRO stock can currently be purchased for approximately $19.52. How much money does Nevro make? Nevro (NYSE:NVRO) has a market capitalization of $705.06 million and generates $406.36 million in revenue each year. The medical equipment provider earns $3 million in net income (profit) each year or $0.01 on an earnings per share basis. How many employees does Nevro have? The company employs 1,087 workers across the globe. How can I contact Nevro? Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The official website for the company is www.nevro.com. The medical equipment provider can be reached via phone at (650) 251-0005 or via email at ir@nevro.com. This page (NYSE:NVRO) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nevro Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.